Tissue perfusion and oxygenation with blood substitutes

Area of Science:

• Biomedical Engineering
• Hematology
• Critical Care Medicine

Background:

• Red blood cell transfusions are standard for severe anemia but carry risks.
• Artificial oxygen carriers are being developed as alternatives to red blood cells.
• Two main types, hemoglobin solutions (SFH) and perfluorocarbons (PFC), are under investigation.

Purpose of the Study:

• To evaluate the efficacy of intravenously administered artificial oxygen carriers.
• To compare the utility of stroma-free hemoglobin solutions (SFH) and perfluorocarbons (PFC) in treating acute severe anemia.
• To assess their role in conditions like hemorrhagic shock and acute normovolemic hemodilution (ANH).

Main Methods:

• Comparison of SFH and PFC artificial oxygen carriers.
• Administration of SFH for blood loss replacement and isovolemic exchange.
• Administration of PFCs at restricted doses for supplemental oxygenation.

Main Results:

• SFH solutions effectively restore and maintain tissue oxygenation in hemorrhagic shock and ANH.
• SFH can be administered in large volumes, suitable for 1:1 blood replacement.
• PFC emulsions require restricted doses due to potential reticuloendothelial system overload and are unsuitable for large-volume replacement.
• Low-dose PFC administration offers a safety margin for tissue oxygenation in hemodiluted subjects.

Conclusions:

• SFH are effective for restoring oxygen-carrying capacity in severe anemia and can be used for substantial blood volume replacement.
• PFCs are not suitable for isovolemic blood replacement but can enhance safety in specific low-dose scenarios.
• Both artificial oxygen carriers show potential but have distinct applications and limitations.